These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 39256860

  • 1. The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer.
    Guo R, Yan W, Wang F, Su H, Meng X, Xie Q, Zhao W, Yang Z, Li N.
    Cancer Imaging; 2024 Sep 10; 24(1):120. PubMed ID: 39256860
    [Abstract] [Full Text] [Related]

  • 2. The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer.
    Tao X, Li N, Wu N, He J, Ying J, Gao S, Wang S, Wang J, Wang Z, Ling Y, Tang W, Zhang Z.
    Eur J Nucl Med Mol Imaging; 2020 May 10; 47(5):1209-1219. PubMed ID: 32043180
    [Abstract] [Full Text] [Related]

  • 3. The utility of 68F-FDG PET/CT for evaluation of tumor response to immune checkpoint inhibitor therapy and prognosis prediction in patients with non-small-cell lung cancer.
    Kitajima K, Kawanaka Y, Komoto H, Minami T, Yokoi T, Kuribayashi K, Kijima T, Nakamura A, Hashimoto M, Kondo N, Hasegawa S, Yamakado K.
    Hell J Nucl Med; 2021 May 10; 24(3):186-198. PubMed ID: 34901959
    [Abstract] [Full Text] [Related]

  • 4. The predictive value of 18F-FDG PET/CT combined with inflammatory index for major pathological reactions in resectable NSCLC receiving neoadjuvant immunochemotherapy.
    Yin X, Li J, Chen B, Liu K, Hu S.
    Lung Cancer; 2023 Dec 10; 186():107389. PubMed ID: 37820538
    [Abstract] [Full Text] [Related]

  • 5. Comprehensive 18F-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: A pilot study.
    Cui Y, Lin Y, Zhao Z, Long H, Zheng L, Lin X.
    Front Immunol; 2022 Dec 10; 13():994917. PubMed ID: 36466929
    [Abstract] [Full Text] [Related]

  • 6. 18F-FDG PET/CT for Very Early Response Evaluation Predicts CT Response in Erlotinib-Treated Non-Small Cell Lung Cancer Patients: A Comparison of Assessment Methods.
    Fledelius J, Winther-Larsen A, Khalil AA, Bylov CM, Hjorthaug K, Bertelsen A, Frøkiær J, Meldgaard P.
    J Nucl Med; 2017 Dec 10; 58(12):1931-1937. PubMed ID: 28490472
    [Abstract] [Full Text] [Related]

  • 7. The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.
    Mattoli MV, Massaccesi M, Castelluccia A, Scolozzi V, Mantini G, Calcagni ML.
    Radiat Oncol; 2017 Jan 05; 12(1):4. PubMed ID: 28057034
    [Abstract] [Full Text] [Related]

  • 8. The role of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant PD-1 blockade in combination with chemotherapy for resectable esophageal squamous cell carcinoma.
    Wang X, Yang W, Zhou Q, Luo H, Chen W, Yeung SJ, Zhang S, Gan Y, Zeng B, Liu Z, Feng S, Zhang X, Cheng C.
    Eur J Nucl Med Mol Imaging; 2022 Oct 05; 49(12):4241-4251. PubMed ID: 35732974
    [Abstract] [Full Text] [Related]

  • 9. Prognostic Value of the Volumetric Parameters of Dual-Time-Point 18F-FDG PET/CT in Non-Small Cell Lung Cancer Treated With Definitive Radiation Therapy.
    Okazaki E, Seura H, Hasegawa Y, Okamura T, Fukuda H.
    AJR Am J Roentgenol; 2019 Dec 05; 213(6):1366-1373. PubMed ID: 31509426
    [Abstract] [Full Text] [Related]

  • 10. Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in resectable non-small cell lung cancer.
    Hughes DJ, Josephides E, O'Shea R, Manickavasagar T, Horst C, Hunter S, Tanière P, Nonaka D, Van Hemelrijck M, Spicer J, Goh V, Bille A, Karapanagiotou E, Cook GJR.
    Eur Radiol; 2024 Sep 05; 34(9):5889-5902. PubMed ID: 38388716
    [Abstract] [Full Text] [Related]

  • 11. [18F]FDG PET-CT radiomics signature to predict pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicenter study.
    Yang M, Li X, Cai C, Liu C, Ma M, Qu W, Zhong S, Zheng E, Zhu H, Jin F, Shi H.
    Eur Radiol; 2024 Jul 05; 34(7):4352-4363. PubMed ID: 38127071
    [Abstract] [Full Text] [Related]

  • 12. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
    Castello A, Toschi L, Rossi S, Finocchiaro G, Grizzi F, Mazziotti E, Qehajaj D, Rahal D, Lopci E.
    Clin Lung Cancer; 2020 Jan 05; 21(1):28-36. PubMed ID: 31409523
    [Abstract] [Full Text] [Related]

  • 13. [18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma.
    Vos JL, Zuur CL, Smit LA, de Boer JP, Al-Mamgani A, van den Brekel MWM, Haanen JBAG, Vogel WV.
    Eur J Nucl Med Mol Imaging; 2022 May 05; 49(6):2010-2022. PubMed ID: 34957526
    [Abstract] [Full Text] [Related]

  • 14. Total metabolic tumor volume on 18F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy.
    Tricarico P, Chardin D, Martin N, Contu S, Hugonnet F, Otto J, Humbert O.
    J Immunother Cancer; 2024 Apr 22; 12(4):. PubMed ID: 38649279
    [Abstract] [Full Text] [Related]

  • 15. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J.
    J Med Imaging Radiat Oncol; 2016 Apr 22; 60(2):231-8. PubMed ID: 26678718
    [Abstract] [Full Text] [Related]

  • 16. 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Metabolic Parameters Before and After Neoadjuvant Chemotherapy Can Predict the Postoperative Prognosis of Locally Advanced Gastric Cancer.
    Mi L, Zhao Y, Zhao X, Yin F, Yin X, Li N, Shi J, Han X, Duan X, Zhao M, Han G, Wang J.
    Cancer Biother Radiopharm; 2021 Oct 22; 36(8):662-671. PubMed ID: 32783634
    [Abstract] [Full Text] [Related]

  • 17. Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology.
    Cheng Y, Chen ZY, Huang JJ, Shao D.
    Eur Radiol; 2023 Oct 22; 33(10):6625-6635. PubMed ID: 37515634
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan 22; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 19. Dynamic 18 F-FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer.
    Chen ZY, Fu R, Tan XY, Yan LX, Tang WF, Qiu ZB, Qi YF, Li YF, Hou QY, Wu YL, Zhong WZ, Jiang BY.
    Thorac Cancer; 2022 Sep 22; 13(17):2524-2531. PubMed ID: 35822254
    [Abstract] [Full Text] [Related]

  • 20. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
    Bhoil A, Singh B, Singh N, Kashyap R, Watts A, Sarika S, Mittal BR.
    Hell J Nucl Med; 2014 Sep 22; 17(2):90-6. PubMed ID: 24997081
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.